Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) is the first interferon-free regimen and the most effective IFN-sparing regimen launched in the U.S. to date. If new agents with comparable efficacy are approved over the next 18 months as is expected, payers could gain leverage to negotiate lower prices. At least eight other programs are in registration or Phase